ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143
Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, Sahebjam S, Lim M, Strauss L, Latek R, Zwirtes R, Paliwal P, Harbison C, Sampson J. ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143. Neuro-Oncology 2016, 18: vi21-vi21. DOI: 10.1093/neuonc/now212.081.Peer-Reviewed Original ResearchAdverse eventsCheckMate 143Frequent treatment-related adverse eventsTreatment-related serious adverse eventsFirst prospective clinical trialProgression/unacceptable toxicityTreatment-related adverse eventsCombination of nivolumabTolerability of nivolumabSerious adverse eventsDeath-1 receptorProspective clinical trialsNew safety concernsMonoclonal antibody inhibitorMultiple cancer typesMeasurable diseaseNivolumab CombinedSafety cohortToxic deathsTumor flareRadiographic progressionTreatment discontinuationMost patientsUnacceptable toxicityPoor prognosis